<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552694</url>
  </required_header>
  <id_info>
    <org_study_id>41052</org_study_id>
    <secondary_id>41052</secondary_id>
    <nct_id>NCT01552694</nct_id>
  </id_info>
  <brief_title>Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation</brief_title>
  <official_title>A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia for Reducing Inflammation and Increasing EPC Number in HIV Infected Men and Women With Insulin Resistance and Central Adiposity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People living with human immunodeficiency virus infection (HIV) have 2-4fold greater risk for
      developing diabetes and heart disease than the general population. They need safe and
      effective treatments that reduce the risk for developing diabetes and heart disease, and
      improve their quality of life. This project will explore whether a new anti-diabetes
      medication (Januvia) with a novel mechanism of action reduces inflammation, and improves
      blood vessel function in HIV infected men and women with several risk factors for developing
      cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People living with human immunodeficiency virus (HIV+) infection have a 2-fold greater
      prevalence and incidence of T2DM and cardiovascular disease (CVD) than the general
      population. The investigators lack safe and effective treatments for these HIV related
      cardiometabolic complications despite the fact that HIV infected adults represent an ideal
      clinical population in which to study interactions among chronic low-grade pro-inflammatory
      processes that are linked to the development of adipose accumulation, insulin resistance,
      ß-cell secretory failure, vascular endothelial dysfunction, atherosclerosis and CVD.
      Dipeptidyl peptidase-IV (DPP4)-inhibitors represent a new drug class that safely and
      effectively regulate glycemia in T2DM, but have not been adequately tested in HIV. Of note,
      pre-clinical studies suggest that DPP4-inhibitors have several pleiotropic actions that may
      specifically benefit people living with HIV infection. For example, DPP4 inhibition reduced
      adipose macrophage infiltration &amp; inflammation and increased the number of bone-derived
      endothelial progenitor cells in the circulation. Our preliminary findings indicate that DPP4
      inhibition is virologically and immunologically safe in non-diabetic HIV+ adults taking
      combination antiretroviral therapy (in preparation), but the potential pleiotropic benefits
      have not been examined in HIV. The investigators propose a randomized, double blind, placebo
      controlled physiological study to test 2 potential pleiotropic benefits of DPP4 inhibition
      (100 mg sitagliptin/d, 8 wk): reduce circulating and adipose-specific markers of
      inflammation; and increase endothelial progenitor cell numbers used for vascular repair in 36
      HIV+ adults with insulin resistance, central adiposity and CVD risk factors. The
      investigators hypothesize that sitagliptin will reduce circulating cytokine levels, reduce
      adipose tissue macrophage number and inflammation, and increase the number of circulating
      endothelial progenitor cells in HIV infected men and women. These physiological studies will
      advance our understanding about the efficacy of DPP4 inhibition in this high-risk group, and
      may help prevent the inexorable transition from insulin resistance to T2DM and CVD in HIV
      infected men and women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Biomarker 1: Plasma hsCRP Concentration</measure>
    <time_frame>2 months</time_frame>
    <description>Fasting serum and plasma samples obtained at baseline and week 8 are batched for ELISA analysis (end of sudy) of hsCRP, IL-6 and D-dimer concentrations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Biomarker 2: Plasma IL-6 Concentration</measure>
    <time_frame>2 months</time_frame>
    <description>There are 3 levels of the primary outcome measure; hsCRP, IL-6, and D-dimer concentrations measured at baseline and week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Biomarker 3: Serum D-dimer Concentration</measure>
    <time_frame>2 months</time_frame>
    <description>There are 3 levels of the primary outcome measure, hsCRP, IL-6, and D-dimer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fold Change in Adipose Inflammation Marker CCL2 (MCP-1) mRNA Expression</measure>
    <time_frame>Baseline to 2 months</time_frame>
    <description>Adipose tissue from obese, insulin resistant subjects is characterized by increased macrophage infiltration and overexpression of inflammatory cytokines/chemokines. In adipose samples, mRNA expression for the macrophage inflammation marker CCL2 (MCP-1) was quantified. Fold change between population averages from baseline to 2 months for adipose macrophage CCL2 (MCP-1) mRNA expression is the outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Blood Endothelial Progenitor Cells</measure>
    <time_frame>Baseline to 2 months</time_frame>
    <description>Monocytes (PBMC) are isolated from 20 mL blood. CD34+/VEGFR2+/KDR+ monocytes represent cell markers for endothelial progenitor cells (EPC). CD34+/VEGFR2+/KDR+ monocytes are counted (flow cytometry) and expressed as a percentage of PBMC number. Percent change between population averages from baseline to 2 months for the EPC/PBMC ratio is calculated and reported as the outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Inflammation</condition>
  <condition>Macrophage Infiltration</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg sitagliptin/day for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo daily for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Oral, 100 mg/day for 2 months</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, matching placebo daily for 2 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 yr old HIV infected men and women.

          -  Stable (at least the past 6 months) on combined antiretroviral therapy (cART).

          -  Stable immune (&gt; 300 CD4+ T-cells/µL) and virologic (&lt; 50 copies HIV RNA/mL) status.

          -  Insulin resistant/impaired glucose tolerance (fasting glucose 100-125mg/dL, or 2-hr
             glucose 140-200mg/dL or fasting HOMA-IR= 2.5-6.0).

          -  Waist circumference &gt; 102 cm (men), &gt; 88 cm (women).

          -  BMI &gt; 20 kg/m2.

          -  Fasting hypertriglyceridemia &gt; 150 mg/dL.

          -  Low HDL-cholesterol (&lt; 40 mg/dL in men or &lt; 50 mg/dL in women).

          -  Platelet count &gt; 30,000/mm3.

          -  Absolute neutrophil count &gt; 750/mm3.

          -  Transaminases &lt; 2.5x the upper limit of normal.

          -  Long-term non-progressors (not taking anti-HIV medications) are not eligible.

        Exclusion Criteria:

          -  Diabetes (T2DM, IDDM or diabetic ketoacidosis) or taking any glucose-lowering
             medication (e.g., insulin, TZDs, metformin, sulfonylurea).

          -  Any agent that might artifactually alter glycemic control (e.g., glucocorticoids,
             megace, rhGH, GH-secretagogue, testosterone derivatives, creatine monohydrate,
             chromium picolinate, AA/protein supplements, medium- or long-chain fatty acids) during
             6 months prior to or during enrollment.

          -  History of serious CV disease. NYHA Functional Class III or IV (e.g., recent MI,
             unstable angina, edema, CHF, CAD, CABG, stroke, resting hypertension &gt; 160/95 mmHg),
             irregular heart rhythm, resting ST-segment depression &gt; 1mm). Treatment with
             medications for CV condition (e.g., α- or ß-blockers). Some BP-lowering medications
             (Ca++channel blocker, diuretic, or ACE inhibitor) are permitted.

          -  Moderate to severe renal insufficiency. Serum creatinine &gt; 1.7 mg/dL (men) &gt; 1.5 mg/dL
             (women).

          -  Plan or anticipate a change in anti-HIV medications during the study.

          -  Lipid-lowering medications are permitted (fibrate or statin or niacin), but must be
             stable on that agent for at least 6 months prior to enrollment. Lipid-lowering agents
             cannot be started during the treatment period.

          -  Chronic hepatitis B (HBV-surface antigen positive). Active hepatitis C (detectable Hep
             C RNA).

          -  Positive urine drug test for opiates, methamphetamine, heroin, cocaine. Active
             substance abuse that the MD-scientist believes may compromise safety, compliance,
             interfere with study drug or data interpretation.

          -  Hematocrit &lt; 34% in men or &lt; 25% in women with symptoms (fatigue, &quot;tired-legs&quot;,
             shortness of breath). Hemoglobin &lt; 10 gm/dL with symptoms.

          -  Pregnant or nursing mothers. Women must agree to use an acceptable form of birth
             control during the study. If using birth control pills-must be stable on this
             medication for at least 6 months prior to enrollment.

          -  Active malignancy or treatment with chemotherapeutic agents or radiation therapy or
             any cytokine or anti-cytokine therapy during 6 months prior to enrollment.

          -  History of pancreatitis

          -  &gt; 10% unintentional weight loss during the 6 months prior to enrollment.

          -  Reduced cognitive function/unable to provide voluntary informed consent. Prisoners are
             excluded.

          -  Blinded investigational drugs for 3 months prior to enrollment that will not be
             unblinded before enrollment.

          -  Nausea, vomiting, diarrhea (&gt; 4 loose stools/day) that are unresponsive to treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin E Yarasheski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://ccs.wustl.edu/</url>
    <description>Center for Clinical Studies- Washington University</description>
  </link>
  <results_reference>
    <citation>Best C, Struthers H, Laciny E, Royal M, Reeds DN, Yarasheski KE. Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance. J Clin Endocrinol Metab. 2015 Jul;100(7):2621-9. doi: 10.1210/jc.2015-1531. Epub 2015 May 4.</citation>
    <PMID>25938633</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2015</results_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kevin Yarasheski, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>cardiometabolic complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>38 participants were initially enrolled. 1 was lost to follow-up; 1 started a personal exercise training program while enrolled in the study. Any data collected on these 2 participants were excluded from the analysis. Both were initially enrolled in the placebo group.</recruitment_details>
      <pre_assignment_details>36 participants completed the trial with complete data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="9"/>
                    <measurement group_id="B2" value="52" spread="6"/>
                    <measurement group_id="B3" value="51" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97" spread="21"/>
                    <measurement group_id="B2" value="102" spread="29"/>
                    <measurement group_id="B3" value="100" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="8.2"/>
                    <measurement group_id="B2" value="33.1" spread="8.2"/>
                    <measurement group_id="B3" value="32.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106" spread="19"/>
                    <measurement group_id="B2" value="112" spread="23"/>
                    <measurement group_id="B3" value="109" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124" spread="15"/>
                    <measurement group_id="B2" value="127" spread="14"/>
                    <measurement group_id="B3" value="125" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74" spread="9"/>
                    <measurement group_id="B2" value="78" spread="10"/>
                    <measurement group_id="B3" value="76" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="5.8"/>
                    <measurement group_id="B2" value="14.2" spread="7.5"/>
                    <measurement group_id="B3" value="14.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell count</title>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="731" spread="220"/>
                    <measurement group_id="B2" value="606" spread="218"/>
                    <measurement group_id="B3" value="668" spread="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD8+ T-cell count</title>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1017" spread="542"/>
                    <measurement group_id="B2" value="801" spread="294"/>
                    <measurement group_id="B3" value="909" spread="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Biomarker 1: Plasma hsCRP Concentration</title>
        <description>Fasting serum and plasma samples obtained at baseline and week 8 are batched for ELISA analysis (end of sudy) of hsCRP, IL-6 and D-dimer concentrations.</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Biomarker 1: Plasma hsCRP Concentration</title>
          <description>Fasting serum and plasma samples obtained at baseline and week 8 are batched for ELISA analysis (end of sudy) of hsCRP, IL-6 and D-dimer concentrations.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.2"/>
                    <measurement group_id="O2" value="5.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.6"/>
                    <measurement group_id="O2" value="7.4" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>A priori threshold for statistical significance was p&lt;0.05. Unadjusted p-value compares the change (week 8 - baseline) for plasma hsCRP between the 2 groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Biomarker 2: Plasma IL-6 Concentration</title>
        <description>There are 3 levels of the primary outcome measure; hsCRP, IL-6, and D-dimer concentrations measured at baseline and week 8</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Biomarker 2: Plasma IL-6 Concentration</title>
          <description>There are 3 levels of the primary outcome measure; hsCRP, IL-6, and D-dimer concentrations measured at baseline and week 8</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.74"/>
                    <measurement group_id="O2" value="2.61" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.55"/>
                    <measurement group_id="O2" value="2.65" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>A priori threshold for statistical significance was p&lt;0.05. Unadjusted analysis.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Biomarker 3: Serum D-dimer Concentration</title>
        <description>There are 3 levels of the primary outcome measure, hsCRP, IL-6, and D-dimer</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Biomarker 3: Serum D-dimer Concentration</title>
          <description>There are 3 levels of the primary outcome measure, hsCRP, IL-6, and D-dimer</description>
          <units>µg FEU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.20"/>
                    <measurement group_id="O2" value="0.28" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.24"/>
                    <measurement group_id="O2" value="0.31" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <p_value_desc>A priori threshold for statistical significance was p&lt;0.05. Unadjusted analysis</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in Adipose Inflammation Marker CCL2 (MCP-1) mRNA Expression</title>
        <description>Adipose tissue from obese, insulin resistant subjects is characterized by increased macrophage infiltration and overexpression of inflammatory cytokines/chemokines. In adipose samples, mRNA expression for the macrophage inflammation marker CCL2 (MCP-1) was quantified. Fold change between population averages from baseline to 2 months for adipose macrophage CCL2 (MCP-1) mRNA expression is the outcome measure.</description>
        <time_frame>Baseline to 2 months</time_frame>
        <population>Adipose tissue samples were not available from all participants. This secondary outcome includes fewer participants analyzed than the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in Adipose Inflammation Marker CCL2 (MCP-1) mRNA Expression</title>
          <description>Adipose tissue from obese, insulin resistant subjects is characterized by increased macrophage infiltration and overexpression of inflammatory cytokines/chemokines. In adipose samples, mRNA expression for the macrophage inflammation marker CCL2 (MCP-1) was quantified. Fold change between population averages from baseline to 2 months for adipose macrophage CCL2 (MCP-1) mRNA expression is the outcome measure.</description>
          <population>Adipose tissue samples were not available from all participants. This secondary outcome includes fewer participants analyzed than the primary outcome.</population>
          <units>fold change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5"/>
                    <measurement group_id="O2" value="-0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Blood Endothelial Progenitor Cells</title>
        <description>Monocytes (PBMC) are isolated from 20 mL blood. CD34+/VEGFR2+/KDR+ monocytes represent cell markers for endothelial progenitor cells (EPC). CD34+/VEGFR2+/KDR+ monocytes are counted (flow cytometry) and expressed as a percentage of PBMC number. Percent change between population averages from baseline to 2 months for the EPC/PBMC ratio is calculated and reported as the outcome measure.</description>
        <time_frame>Baseline to 2 months</time_frame>
        <population>CD34+/VEGFR2+/KDR+ monocytes (EPC) are a very rare cell type (&lt;1% of PBMC). Not all blood samples contain EPC cells, or there are too few to count reliably. This measure was obtained in a subset of the total participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Blood Endothelial Progenitor Cells</title>
          <description>Monocytes (PBMC) are isolated from 20 mL blood. CD34+/VEGFR2+/KDR+ monocytes represent cell markers for endothelial progenitor cells (EPC). CD34+/VEGFR2+/KDR+ monocytes are counted (flow cytometry) and expressed as a percentage of PBMC number. Percent change between population averages from baseline to 2 months for the EPC/PBMC ratio is calculated and reported as the outcome measure.</description>
          <population>CD34+/VEGFR2+/KDR+ monocytes (EPC) are a very rare cell type (&lt;1% of PBMC). Not all blood samples contain EPC cells, or there are too few to count reliably. This measure was obtained in a subset of the total participants.</population>
          <units>Percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>100 mg sitagliptin/day for 2 months
Sitagliptin: Oral, 100 mg/day for 2 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo daily for 2 months
Placebo: oral, matching placebo daily for 2 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain, shortness of breath, wheezing, cough</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, nausea, vomiting, constipation, diarrhea, hypoglycemia</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatique, Fever, Chills, Loss of appetite, Weight Loss</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus, respiratoy urinary tract infections</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle ache, arthritis, swelling, weakness</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headaches, dizziness ,numbness, depression, anxiety, confusion</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chnages in urinary frequency, painful urination, blood in urine</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash, pruritus, easy bruising</sub_title>
                <description>All Other non-Serious Adverse Events under each organ system category were collected as a single event irrespective of the symptom.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Yarasheski, PhD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>3143628173</phone>
      <email>key@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

